|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4900 CAD | -2.00% |
|
-5.77% | +7.69% |
| 07-14 | PharmaCorp to Seek Acquisition Opportunities | CI |
| 07-14 | PharmaCorp Rx Closes C$11.5 Million Bought-Deal Offering of Share Units | MT |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 85.3 | - | - |
| Change | - | 19.91% | 12.31% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 90.2 | 86.72 | 89.13 |
| Change | - | -15.46% | 68.45% | -3.86% | 2.77% |
| P/E | -54x | -45.5x | 49x | 16.3x | - |
| PBR | - | - | 1.53x | 1.44x | - |
| PEG | - | - | -0x | 0x | - |
| Capitalization / Revenue | - | 3.64x | 1.71x | 0.87x | 0.98x |
| EV / Revenue | - | 2.56x | 1.81x | 0.88x | 1.03x |
| EV / EBITDA | - | 15.2x | 18.4x | 7.76x | 7.84x |
| EV / EBIT | - | - | 40.7x | 12.2x | 10.6x |
| EV / FCF | - | 27.9x | -37.5x | 16.5x | 12.5x |
| FCF Yield | - | 3.58% | -2.66% | 6.07% | 7.99% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | 0.01 | 0.03 | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 49.82 | 98.11 | 86.65 |
| EBITDA 1 | - | 3.528 | 4.911 | 11.18 | 11.37 |
| EBIT 1 | - | - | 2.215 | 7.13 | 8.448 |
| Net income 1 | -1.013 | -1.481 | 1.6 | 7 | - |
| Net Debt 1 | - | -22.4 | 4.903 | 1.424 | 3.828 |
| Reference price 2 | 0.5400 | 0.4550 | 0.4900 | 0.4900 | 0.4900 |
| Nbr of stocks (in thousands) | 117,296 | 166,927 | 174,082 | - | - |
| Announcement Date | 22/04/25 | 29/04/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 49x | 1.81x | 18.37x | - | 60.57M | |
| 17.39x | 0.72x | 11.3x | -.--% | 15.05B | |
| 22.77x | 0.9x | 15.82x | 1% | 6.88B | |
| 16.12x | 0.72x | 7.52x | 2.31% | 5.91B | |
| 13.78x | 0.88x | 6.37x | 3.11% | 3.9B | |
| 13.96x | 1.19x | 7.29x | 5.48% | 3.16B | |
| 14.12x | 0.58x | 4.64x | 4.9% | 3.09B | |
| 14.62x | 0.88x | 6.64x | 4.39% | 2.96B | |
| 39.46x | - | - | - | 2.56B | |
| Average | 22.36x | 0.96x | 9.74x | 3.03% | 4.84B | |
| Weighted average by Cap. | 18.42x | 0.80x | 9.91x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
